

## COL2A1 exon 2 mutations: relevance to the Stickler and Wagner syndromes

Allan J Richards, Sam Martin, John R W Yates, John D Scott, David M Baguley, F Michael Pope, Martin P Snead

### Abstract

**Aims**—To compare the clinical and molecular genetic features of two phenotypically distinct subgroups of families with type 1 Stickler syndrome.

**Background**—Stickler syndrome (hereditary arthro-ophthalmopathy, McKusick Nos 108300 and 184840) is a dominantly inherited disorder of collagen connective tissue, resulting in an abnormal vitreous, myopia, and a variable degree of orofacial abnormality, deafness, and arthropathy. Stickler syndrome is the commonest inherited cause of rhegmatogenous retinal detachment in childhood with a risk of giant retinal tear (GRT) which is commonly bilateral and a frequent cause of blindness.

**Method**—Pedigrees were identified from the vitreoretinal service database and subclassified according to vitreoretinal phenotype. Ophthalmic, skeletal, auditory, and orofacial features were assessed. Linkage analysis was carried out with markers for the candidate genes COL2A1, COL11A1, and COL11A2. The COL2A1 gene was amplified as five overlapping PCR products. Direct sequencing of individual exons identified mutations.

**Results**—Eight families exhibiting the type 1 vitreous phenotype were studied. Seven were consistent for linkage to COL2A1, with lod scores ranging from 2.1 to 0.3. In most instances linkage to COL11A1 and COL11A2 could be excluded. One family was analysed without prior linkage analysis. Three of the families exhibited a predominantly ocular phenotype with minimal or absent systemic involvement and were found to have mutations in exon 2 of COL2A1. Five other pedigrees with an identical ocular phenotype plus orofacial, auditory, and articular involvement had mutations in others regions of the COL2A1 gene. None of the pedigrees exhibited the characteristic lenticular, retinal pigment epithelial, or choroidal changes seen in Wagner syndrome.

**Conclusions**—These data confirm that type 1 Stickler syndrome is caused by mutations in the gene encoding type II collagen (COL2A1). In addition, data are submitted showing that mutations involving exon 2 of COL2A1 are characterised by a predominantly ocular variant of this disorder, consistent with the major form of type II procollagen in non-ocular

tissues having exon 2 spliced out. Such patients are all at high risk of retinal detachment. This has important implications for counselling patients with regard to the development of systemic complications. It also emphasises the importance and reliability of the ophthalmic examination in the differential diagnosis of this predominantly ocular form of Stickler syndrome from Wagner's vitreoretinopathy.

(Br J Ophthalmol 2000;84:364–371)

Stickler syndrome (hereditary arthro-ophthalmopathy, McKusick Nos 108300 and 184840) is a dominantly inherited disorder of collagen connective tissue,<sup>1,2</sup> resulting in an abnormal vitreous and a variable degree of orofacial abnormality, deafness, and arthropathy. It is the commonest inherited cause of rhegmatogenous retinal detachment in childhood. Although the systemic features are widespread, the sight threatening complications are perhaps the most conspicuous and serious manifestations, particularly the risk of giant retinal tear (GRT) which is frequently bilateral and, if untreated, leads to blindness.

Abnormalities of vitreous gel formation and architecture are pathognomonic of Stickler syndrome<sup>3</sup> and two distinct vitreoretinal phenotypes are now recognised. The majority of families show a characteristic congenital “membranous” vitreous anomaly (type 1) but in a minority a different “beaded” (type 2) phenotype is apparent.<sup>4–7</sup> All families with full Stickler syndrome exhibit an abnormal vitreoretinal phenotype, but other systemic changes can be highly variable both between and within families.

The first mutation in a family with Stickler syndrome was identified in COL2A1,<sup>8</sup> the gene for type II collagen, a major component of both cartilage and vitreous. The original kindred reported by Stickler also had a mutation in this gene.<sup>9</sup> Both resulted in premature termination codons which appear to be a distinctive feature of the Stickler phenotype compared with other inherited connective tissue dysplasias associated with COL2A1 mutations.<sup>10</sup> It is now known that the type 1 vitreous phenotype, as described by Scott,<sup>4</sup> correlates with defects in type II procollagen (Snead *et al*<sup>5</sup> and unpublished data).

Pedigrees with other varieties of vitreous phenotype are genetically heterogeneous. Some have mutations in COL11A1 the gene for  $\alpha 1(XI)$  collagen, one of two type XI  $\alpha$  chains, which form heterotypic fibrils with type

MRC Connective  
Tissue Genetics  
Group, University of  
Cambridge,  
Department of  
Pathology, Cambridge  
CB2 1QP  
A J Richards  
S Martin

Department of  
Medical Genetics,  
University of  
Cambridge  
J R W Yates

Vitreoretinal Service,  
Department of  
Ophthalmology  
J D Scott  
M P Snead

Department of  
Audiology,  
Addenbrooke's  
Hospital, Hills Road,  
Cambridge CB2 2QQ  
D M Baguley

Institute of Medical  
Genetics, University  
Hospital of Wales,  
Heath Park, Cardiff  
CF4 4XN  
F M Pope

Correspondence to:  
Martin P Snead,  
Vitreoretinal Service,  
Addenbrooke's Hospital,  
Hills Road, Cambridge  
CB2 2QQ

Accepted for publication  
21 December 1999

Table 1 Phenotypes resulting from COL2A1 mutations not in exon 2. Clinical manifestations were scored as 0 absent, 1 mild, 2 moderate, and 3 severe, except for retinal detachments which was scored 1 single eye or 2 both eyes

| Family     | Ocular phenotype |                    | Articular phenotype |                                | Aural phenotype |                   | Oro-facial phenotype |                            |                  |
|------------|------------------|--------------------|---------------------|--------------------------------|-----------------|-------------------|----------------------|----------------------------|------------------|
|            | Myopia           | Retinal detachment | Joint hypermobility | Radiological joint abnormality | Conductive loss | Sensoineural loss | Midfacial hypoplasia | Abnormal nasal development | Midline clefting |
| MS2        |                  |                    |                     |                                |                 |                   |                      |                            |                  |
| II-2       | 3                | NA                 | 1                   | 1                              | 0               | 0                 | 1                    | 0                          | 3                |
| III-1      | 2                | NA                 | 1                   | 0                              | 2               | 0                 | 0                    | 0                          | 3                |
| III-2      | 3                | NA                 | 0                   | 0                              | 2               | 1                 | 2                    | 2                          | 3                |
| MS18       |                  |                    |                     |                                |                 |                   |                      |                            |                  |
| II-2       | 2                | 0                  | 2                   | 2                              | 0               | 3                 | 1                    | 1                          | 3                |
| III-1      | 2                | 0                  | 2                   | 1                              | ND              | ND                | 1                    | 2                          | 3                |
| MS20       |                  |                    |                     |                                |                 |                   |                      |                            |                  |
| II-1       | 2                | NA                 | 2                   | 1                              | 0               | 2                 | 2                    | 2                          | 2                |
| II-4       | 0                | 2                  | 1                   | ND                             | 1               | 1                 | 2                    | 0                          | 2                |
| II-5       | 0                | 1                  | 0                   | 2                              | 0               | 0                 | 0                    | 1                          | 2                |
| III-1      | 3                | 2                  | 3                   | 0                              | 3               | 3                 | 2                    | 1                          | 3                |
| III-2      | 3                | NA                 | 2                   | 0                              | 0               | 2                 | 2                    | 1                          | 2                |
| MS54       |                  |                    |                     |                                |                 |                   |                      |                            |                  |
| I-1        | 2                | 1                  | 0                   | 1                              | 0               | 2                 | 1                    | 1                          | 2                |
| II-2       | 0                | 2                  | 0                   | 1                              | 1               | 0                 | 1                    | 1                          | 0                |
| MS66       |                  |                    |                     |                                |                 |                   |                      |                            |                  |
| I-2        | 1                | 2                  | 1                   | 2                              | 0               | 1                 | 0                    | 1                          | 0                |
| II-2       | 1                | 1                  | 2                   | 2                              | 0               | 0                 | 1                    | 2                          | 1                |
| III-1      | 1                | 0                  | 0                   | 0                              | 1               | 0                 | 1                    | 1                          | 3                |
| Mean score | 1.7              | 1.1                | 1.1                 | 0.9                            | 0.7             | 1.0               | 1.1                  | 1.1                        | 2.1              |

NA = not applicable because of prophylactic treatment. ND = not determined.

II collagen.<sup>6,7</sup> These pedigrees feature sparse and irregularly thickened bundles of “beaded” fibres (type 2 vitreous phenotype) throughout the vitreous cavity. It is not yet clear whether this is specific to mutations in COL11A1 or may also result from defects at other loci. The other polypeptide chain ( $\alpha 2$ ) of type XI collagen is not expressed in the vitreous<sup>11</sup> so that mutations in its encoding gene (COL11A2) produce a syndrome with the systemic features of Stickler syndrome but without eye involvement.<sup>12-16</sup> Evidence for another Stickler syndrome locus also exists.<sup>7,17</sup>

Type II procollagen exists in two alternatively spliced forms. A short form, which is expressed in cartilage, has exon 2 spliced out, resulting in a molecule with a smaller N-propeptide ( $\alpha$ IIb). The short form also functions as a third  $\alpha$ (XI) chain in cartilage. It co-assembles with products of the COL11A1 and COL11A2 genes, to form a  $\alpha 1$ (XI)  $\alpha 2$ (XI)

$\alpha 1$ (IIb) heterotrimer. Thus, mutations in COL2A1 can affect both type II and XI collagen in this tissue.<sup>18</sup> In vitreous both transcripts exist but here the longer form predominates.<sup>19</sup> It is unclear whether this longer form can also participate in heterotrimer formation with  $\alpha 1$ (XI) collagen

Of the Stickler syndrome pedigrees exhibiting the type 1 vitreous phenotype, a subgroup has also been identified that is characterised by a predominantly ocular disorder without systemic skeletal or auditory involvement. Before the introduction of the subclassification of Stickler syndrome based on vitreous phenotype it is possible that some of these pedigrees might otherwise have been confused with another inherited vitreoretinopathy, Wagner syndrome (MIM 143200<sup>20,21</sup>). However, although Wagner syndrome also appears to be a predominantly ocular vitreoretinopathy without systemic manifestations, it has distinct

Table 2 Phenotypes resulting from COL2A1 exon 2 mutations. Clinical manifestations were scored as 0 absent, 1 mild, 2 moderate, and 3 severe, except for retinal detachment, which was scored 1 single eye or 2 both eyes

| Family     | Ocular phenotype |                    | Articular phenotype |                                | Aural phenotype |                   | Oro-facial phenotype |                            |                  |
|------------|------------------|--------------------|---------------------|--------------------------------|-----------------|-------------------|----------------------|----------------------------|------------------|
|            | Myopia           | Retinal detachment | Joint hypermobility | Radiological joint abnormality | Conductive loss | Sensoineural loss | Midfacial hypoplasia | Abnormal nasal development | Midline clefting |
| Ms11       |                  |                    |                     |                                |                 |                   |                      |                            |                  |
| I-2        | 0                | 2                  | 0                   | ND                             | 0               | 2                 | 0                    | 0                          | 0                |
| II-2       | 3                | 2                  | 0                   | 0                              | 0               | 0                 | 0                    | 0                          | 0                |
| II-5       | 3                | 2                  | 0                   | 0                              | 0               | 0                 | 0                    | 0                          | 0                |
| III-1      | 3                | 2                  | 1                   | 0                              | 0               | 1                 | 0                    | 0                          | 0                |
| III-4      | 3                | 0                  | 1                   | 0                              | 0               | 0                 | 0                    | 0                          | 0                |
| MS13       |                  |                    |                     |                                |                 |                   |                      |                            |                  |
| I-1        | 3                | 2                  | 0                   | 0                              | 0               | 0                 | 0                    | 0                          | 0                |
| II-1       | 3                | 1                  | 0                   | 0                              | 1               | 1                 | 0                    | 0                          | 0                |
| II-2       | 3                | NA                 | 0                   | 0                              | 2               | 1                 | 0                    | 0                          | 3                |
| II-4       | 1                | NA                 | 0                   | 0                              | 0               | 0                 | 0                    | 0                          | 0                |
| II-6       | 0                | 1                  | 0                   | ND                             | 0               | ND                | 1                    | 0                          | 0                |
| MS62       |                  |                    |                     |                                |                 |                   |                      |                            |                  |
| II-1       | 0                | 2                  | 0                   | 0                              | 0               | 1                 | 1                    | 0                          | 0                |
| II-3       | 0                | 2                  | 0                   | 1                              | 0               | 0                 | 0                    | 0                          | 0                |
| III-2      | 0                | 2                  | 0                   | 0                              | 0               | 0                 | 1                    | 0                          | 2                |
| III-3      | 3                | 0                  | 0                   | 0                              | 1               | 1                 | 2                    | 0                          | 3                |
| III-5      | 2                | 2                  | 0                   | 0                              | 0               | 0                 | 2                    | 0                          | 0                |
| III-6      | 2                | 1                  | 0                   | 0                              | 0               | 1                 | 1                    | 0                          | 0                |
| Mean score | 1.8              | 1.5                | 0.1                 | 0.1                            | 0.2             | 0.5               | 0.5                  | 0                          | 0.5              |

NA = not applicable because of prophylactic treatment. ND = not determined.




Figure 1 Mutation detection by sequencing. Mutations in exon 2 are shown for families MS11, MS13, and MS62 along with the normal sequence (N). The sequence for each is written under the chromatograms. For the frameshifts the mutant sequence is shown from the point at which the sequence becomes heterozygous, is in bold type, and is also indicated in the normal sequence. A 2 bp deletion and 4 bp duplication are boxed. The translated products are shown above and below the normal and mutant sequences respectively. The premature stop codons resulting from the frameshifts are underlined.

clinical differences from Stickler syndrome,<sup>22 23</sup> and in some families linked to a separate locus on chromosome 5.<sup>22 24 25</sup> The term “Wagner-Stickler” syndrome,<sup>26–29</sup> is therefore confusing and should be abandoned.

Here we describe the clinical and molecular genetic features of eight families with Stickler syndrome. All eight families feature the same type 1 vitreous phenotype but three of the families have a predominantly ocular phenotype with minimal or absent systemic involvement and were found to have mutations in

exon 2 of COL2A1. Five other pedigrees have, in addition to the type 1 ocular phenotype, auditory and articular involvement and have mutations in others regions of the same gene. None of the pedigrees exhibits the characteristic lenticular, retinal pigment epithelial, or choroidal changes seen in Wagner syndrome.<sup>22 23</sup>

## Method

### CLINICAL EXAMINATION

Pedigrees were identified from the vitreous clinic database at Addenbrooke’s Hospital and subclassified prospectively according to vitreoretinal phenotype before molecular genetic analysis. Informed written consent was received in all cases and prior ethical approval for the study was obtained (LRC92/019).

### OPHTHALMIC EXAMINATION

A general ophthalmic history was recorded with particular attention to the age of onset, degree and progression of myopia, cataract, and vitreoretinal disease. A full ophthalmic examination including refraction, slit lamp biomicroscopy, indirect ophthalmoscopy, and B scan ultrasonography was carried out. In some of the younger patients applanation tonometry and gonioscopy were not possible. Anterior and posterior segment photographs were taken where appropriate.

### PHYSICAL DEVELOPMENT

In order to assess the developmental morphology of the face and hands, all patients were examined subjectively and objectively. A subjective assessment was made of the non-quantifiable factors retrognathia and anteversion of nares. All other factors were measured objectively according to a standardised method.<sup>30</sup> Anteroposterior and lateral facial photographs were taken at a standardised scale of 1:8, and of both hands at a scale of 1:10 using a Nikon FM2 camera with Micro Nikon 105 mm medical lens and Kodachrome 64 film at F16. A 1 cm grid was printed and then photographed at a scale of 1:8 to match the facial films and 1:10 to match the hand views. Clinical measurements of outer canthal distance, inner canthal distance, philtrum length, and middle finger length were also recorded at the time of initial examination. These were used subsequently to test the accuracy of the method of photographic calibration. Control measurements of inner and outer canthal distance, interpupillary distance, and philtrum length from 20 unaffected siblings and 60 age matched controls (recruited from the general ophthalmic clinic) were also recorded.

Using dual projection of identically calibrated projectors, the matched scales were superimposed over each facial view in turn so that the quantifiable facial measurements could be made. This was repeated using the matched scale for the hand views. All measurements were made according to published criteria.<sup>30</sup>




Figure 2 Family confirmation of frameshift mutations. <sup>32</sup>P labelled single dideoxynucleotide, sequencing reactions (as indicated) were performed on PCR products amplified from individual family members. Numbers indicate nucleotide sequence (Accession No L10347). Asterisks indicate extra bands seen in affected family members.

#### GENERALISED SKELETAL COMPLEX

Height and weight were measured and an assessment made of general body build. Joint hypermobility was assessed objectively using the Beighton scoring system. A score of one or zero is given for a series of joint manoeuvres and the total sum allocated up to a possible maximum score of 9/9. This method allows comparison with published age and sex matched populations.<sup>31</sup> Plain anteroposterior and lateral radiographs were carried out on affected pedigree members.

#### AUDIOLOGY EXAMINATION

A specific inquiry was made regarding the date and progression of any subjective hearing loss and in particular whether this had been a congenital, sudden, or progressive deterioration. A record of the type and duration of noise exposure was made together with any contributory factors such as glue ear, grommets, or drug induced sensorineural damage. All affected patients underwent bilateral otoscopy and audiometry involving air and bone conduction testing according to standardised procedures.<sup>32</sup>

#### MOLECULAR GENETIC ANALYSIS

Seven families with the type 1 vitreous phenotype were used for linkage analysis to markers for COL2A1, COL11A1, and COL11A2 as previously described.<sup>7</sup> All were consistent for linkage to COL2A1, with lod scores ranging from 2.1 to 0.3. In most instances COL11A1 and COL11A2 could be excluded (data not shown). Another family with the type 1 vitreous phenotype was used without any linkage analysis. All eight were analysed for COL2A1 mutations.

#### COL2A1 AMPLIFICATION AND SEQUENCING

Database available DNA sequences were used to design primers for polymerase chain reaction (PCR) amplification. A 30.991 kb sequence contained exons 1–54 (Accession No L10347); 343 bp of 3' untranslated region was contained in an EST Image clone (Accession No H62509). Five PCR products covering bases (1) 4052–6902, (2) 6028–11591, (3) 11331–19598, (4) 18342–26231, (5) 24171–30991+106 3'UTR were amplified using DNA from a second or third generation affected individual. In each case the primers

**Table 3** Type and position of COL2A1 mutations. The position and type of mutations found in COL2A1 are indicated by nucleotide location within the COL2A1 gene (Accession No L10347) Amino acids are numbered by the usual convention in which the first glycine of the triple helical region is 1. Amino acids in the N-propeptide are numbered from the initiating methionine

| Family | Lod score<br>( $Z_{\max}$ , $\theta=0$ ) | Mutation       | Exon | Effect                      |
|--------|--|----------------|------|-----------------------------|
| MS62   | 0.8                                      | 4246 G-A       | 2    | W47X (N-propeptide)         |
| MS11   | 2.1                                      | 4266 ins 4 bp  | 2    | Frameshift: stop in exon 2  |
| MS13   | 1.1                                      | 4269 del 2 bp  | 2    | Frameshift: stop in exon 2  |
| MS54   | Not analysed                             | 17189 del 1 bp | 21   | Frameshift: stop in exon 28 |
| MS2    | 0.3                                      | 22314 C-T      | 35   | R585X                       |
| MS66   | 0.3                                      | 25671 ins C    | 42   | Frameshift: stop in exon 42 |
| MS20   | 1.1                                      | 25716 C-T      | 42   | R732X                       |
| MS18   | 0.5                                      | 25734 ins C    | 42   | Frameshift: stop in exon 42 |

$Z_{\max}$  = maximum lod score,  $\theta$  = recombination fraction.

for PCR corresponded to the first 24 sense and last 24 antisense nucleotides of each product. Amplification reactions used TaqPlus (Stratagene) as previously described.<sup>7</sup> Products were purified using QIAquickspin columns (Qiagen), and eluted in water. Direct cycle sequencing of individual exons contained within the PCR products was performed with BigDye terminator RR mix (PE Applied Biosystems). Sequencing primers were situated around 50 bp up and downstream from each exon and were derived from the published sequence for the COL2A1 gene (Accession No L10347). Reactions were analysed using an ABI 377 machine.

#### FAMILY DNA ANALYSIS

Smaller regions of COL2A1 containing potential mutation sites, identified by sequencing, were amplified, from each family member. Taq DNA polymerase (Life Technologies) was used with amplification conditions described previously.<sup>6</sup> Products were purified as above and used in a <sup>33</sup>P labelled single dideoxynucleotide sequencing reaction, such that the base change under test could be detected. Thermo-sequenase version II (Amersham International) was used for the direct sequencing reaction. Products were separated by electrophoresis in a denaturing polyacrylamide gel and then autoradiographed. Spouses marrying into the family were used as normal controls.

#### Results

The type 1 vitreous anomaly was present in all affected individuals and clinical status was confirmed on subsequent mutation analysis (see below). Although there was both interfamilial and intrafamilial variation in systemic phenotype the vitreous phenotype remained consistent throughout and this emphasises the importance of vitreous slit lamp examination in this disorder. Five families (MS2, MS18, MS20, MS54, and MS66) expressed significant auditory and skeletal abnormalities in addition to their ocular changes. The remaining three families (MS11, MS13, and MS62) expressed a predominantly ocular phenotype in which skeletal, auditory changes were minimal and orofacial abnormalities were present only in a minority of individuals. These differences are illustrated and quantified in Tables 1 and 2. In seven families linkage analysis was consistent with COL2A1 as the disease locus.

An additional family (MS54) was analysed solely on the basis of the vitreous phenotype.

The COL2A1 gene was amplified as five overlapping PCR products and individual exons were directly sequenced. In all cases changes to the sequence which lead to premature termination codons and haploinsufficiency were found (examples are shown in Fig 1). Five of these were frame shift mutations and three were single base substitutions (Table 3). Mutations in each family were confirmed by single dideoxynucleotide sequencing reactions designed to detect the abnormality. In each case the status of affected and normal individuals, as determined by slit lamp examination before molecular analysis, was confirmed by mutation detection. All but one of these mutations are novel and, because they result in premature termination codons, they would be very unlikely to occur in the general population.

Three mutations were in exon 2. Two of these were frame shift mutations, a 2 bp deletion, and a 4 bp duplication (GGAT) (Fig 2). Both lead to a premature termination codon at the same position in exon 2. The third exon 2 mutation was a single base substitution, which converted a codon for tryptophan to a premature termination codon. Two other frame shifts were both in exon 42 and were insertions of a single cytosine residue into different poly C sequences. These lead to premature termination codons in different positions in the cDNA sequence. Another frameshift mutation was caused by a 1 bp deletion in exon 21. This led to a downstream premature termination codon, in exon 28. Two single base substitutions converting codons for arginine to stop codons were seen in exons 35 and 42. The stop codon mutation in exon 42 was identical to the first Stickler mutation characterised by Ahmad *et al* in 1991.<sup>8</sup>

The three families with exon 2 mutations corresponded to those with minimal systemic changes (MS11, MS13, and MS62) (Table 2). Articular changes were absent in all except an 80 year old member of family MS62. It is of interest and importance to note, however, that the risk of ophthalmic complications (myopia, retinal detachment) is high in both groups of families. Although midline clefting was less common in the families with exon 2 mutations the number of patients is too small for statistical analysis.

#### Discussion

The Stickler and Wagner syndromes are both dominantly inherited vitreoretinopathies and one of the main criteria often used to distinguish between the two is the lack of systemic features in the Wagner syndrome. Wagner<sup>20</sup> described a new ocular disease in a three generation pedigree from the Kanton of Zurich with 13 affected individuals. It featured autosomal dominant inheritance, low myopia (3.00 dioptres or less), fluid vitreous, cortical cataract, and inconstant and variably affected dark adaptation. No affected individual suffered a retinal detachment. In a follow up study of Wagner's original pedigree,<sup>21</sup> 10 further affected individuals were identified. The cardi-




Figure 3 Family confirmation of premature termination codons. <sup>33</sup>P labelled single dideoxynucleotide, sequencing reactions (as indicated) were performed on PCR products amplified from individual family members. Numbers indicate nucleotide sequence (Accession No L10347). The extra bands seen in affected members are arrowed.

nal features noted were the complete absence of the normal vitreal scaffolding and preretinal, equatorial, and avascular greyish-white membranes. Clear lenses in childhood developed anterior and posterior cortical opacities in puberty and cataracta complicata during the

fourth decade. Rhegmatogenous retinal detachment was not reported in either publication but has since been noted in a minority of individuals.<sup>33</sup>

The association of retinal detachment and cleft palate was noted before Stickler's descrip-

Table 4 Comparison of ophthalmic features in type 1 Stickler syndrome and Wagner syndrome

|                                   | Stickler syndromes  | Wagner syndrome  |
|-----------------------------------|---|--|
| Myopia                            | Congenital, high degree   | Usually mild   |
| Anterior chamber angle dysgenesis | Occasional  | Unreported   |
| Cataract                          | Wedge-shaped, cortical<br>Frequently non-progressive            | Early onset, nuclear, progressive, "cataracta complicata"    |
| Type 1 vitreous anomaly           | Present   | Absent   |
| Retinopathy                       | Frequently normal<br>scalloped paravascular pigmented lattice   | Progressive pigmentary and punched out chorioretinal atrophy |
| Retinal detachment                | Common, frequently bilateral<br>High risk of giant retinal tear | Uncommon   |
| Dark adaptation                   | Normal  | May be reduced   |




Figure 4 Vitreous phenotypes in Stickler syndrome. (A) Type 1 phenotype: COL2A1 non-exon 2 family MS20. (B) Type 1 phenotype: COL2A1 exon 2 family MS13. (C) Type 2 phenotype: COL11A1 mutation (data not shown, family MS42 see Martin *et al*).

tion of hereditary arthro-ophthalmopathy<sup>34</sup> and controversy arose regarding the authenticity of the proposed new syndrome. Indeed, many subsequent publications referred to the “Wagner-Stickler” syndrome,<sup>26–29 35</sup> or “Wagner syndrome with arthropathy”<sup>36</sup> implying phenotypic variation of the same basic underlying disorder. It has subsequently been shown that families with Stickler syndrome and a non-ocular variant have mutations in the genes COL2A1, COL11A1, and COL11A2; whereas, several families with Wagner syndrome (WGN1) including the original family have been linked to a locus at 5q14.3.<sup>24 25</sup>

The mutations in COL2A1 exon 2 described here illustrate the critical importance of ophthalmic and particularly vitreous examination in distinguishing between these two disorders, especially if a pedigree is too small to exclude one or other loci on linkage analysis. The main clinical differences are summarised in Table 4.

There has been one report of a COL2A1 mutation causing Wagner syndrome.<sup>37</sup> However, the clinical description including the mild facial hypoplasia and hypermobile joints more closely resembled that of Stickler syndrome. In our experience the ocular phenotype displayed

by COL2A1 exon 2 mutation patients matches that seen in other COL2A1 Stickler syndrome families. Patients exhibit the membranous congenital anomaly and do not show the atrophy of the retinal pigment epithelium and choriocapillaris seen in 5q linked Wagner families (Table 4). In our view these clinical differences are sufficient to distinguish between the two disorders.

Our results also illustrate that the families with COL2A1 exon 2 mutations, even in the absence of obvious skeletal or auditory features are also at high risk of retinal detachment. This is particularly important since the diagnosis of Stickler syndrome may be overlooked or rejected on the basis of the minimal or absent skeletal changes. Although the midline clefting seen in some individuals might suggest Stickler syndrome, most patients have few if any non-ocular characteristics normally associated with this disorder.<sup>38</sup>

Seven individuals with exon 2 mutations had some degree of midfacial hypoplasia or midline clefting, the latter being severe in two cases. This may indicate that the longer  $\alpha$ IIa collagen plays a part during craniofacial development. Certainly, the level of  $\alpha$ IIa mRNA is higher in fetal skeletal tissue.<sup>18 39</sup> In these few individuals where facial hypoplasia or midline clefting is apparent the diagnosis of Stickler syndrome would be acceptable. However, for the majority of exon 2 mutants (including all members of MS11) the lack of extraocular characteristics might, in the view of some clinicians, exclude the designation of Stickler syndrome. A suggested alternative title might be “predominantly ocular” Stickler syndrome (POSS), commensurate with the non-ocular Stickler syndrome (NOSS) phenotype caused by mutations in COL11A2 and “full” Stickler syndrome (FSS) secondary to other mutations in either COL2A1 or COL11A1.

The absence of arthropathy, cleft palate, hearing loss, and cardiovascular abnormalities led Perveen *et al*,<sup>25</sup> to assign a diagnosis of Wagner syndrome in 18 families. However, 14 were too small to confirm linkage to 5q14.3. The lack of mutations in these families was used to exclude the versican (CSPG2) gene as the Wagner locus. The authors themselves were cautious as to whether all of their families might be linked to 5q14.3. We suggest that unless the retinal phenotype was the same as for families linked to 5q14.3, then COL2A1 should be considered a candidate for the disease locus in families with vitreoretinopathy without systemic changes, unless it could be excluded by linkage. It is not known if mutations in other regions of the COL2A1 gene can also lead to similar ocular only phenotypes.

Finally, our family studies emphasise the reliability of vitreous phenotype in the diagnosis of Stickler syndrome. Whereas systemic features vary between and within families the eye changes were remarkably consistent (Fig 4). Of 52 individuals examined (excluding unaffected spouses) mutation detection ratified the clinical diagnosis in 35 affected and 19 unaffected individuals.

The authors gratefully acknowledge the financial support of The Iris Fund for Prevention of Blindness, The Medical Research Council, The Stanley Thomas Johnson Foundation, and Michael and Elizabeth Greig.

We also wish to thank the following: Maureen Laidlaw (tissue culture), Katherine Haslam and Medical Illustration, Addenbrooke's Hospital, Cambridge (photography), Chris Madren, Department of Genetics (sequencing), and our medical colleagues who have kindly referred patients to the vitreoretinal service at Addenbrooke's Hospital.

- 1 Stickler GB, Belau PG, Farrell FJ, *et al.* Hereditary progressive arthro-ophthalmopathy. *Mayo Clinic Proc* 1965;40:433-55.
- 2 Stickler GB, Pugh DG. Hereditary progressive arthro-ophthalmopathy II. Additional observations on vertebral abnormalities, a hearing defect, and a report of a similar case. *Mayo Clinic Proc* 1967;42:495-500.
- 3 Maumenee IH. Vitreo-retinal degeneration as a sign of generalised connective tissue diseases. *Am J Ophthalmol* 1979; 88:432-49.
- 4 Scott JD. Prevention and perspective in retinal detachment. Duke-Elder Lecture. *Eye* 1989;3:491-515.
- 5 Snead MP, Payne SJ, Barton DE, *et al.* Stickler syndrome: correlation between vitreo-retinal phenotypes and linkage to COL 2A1. *Eye* 1994;8:609-14.
- 6 Richards AJ, Yates JRW, Williams R, *et al.* A family with Stickler syndrome type 2 has a mutation in the COL11A1 gene resulting in the substitution of glycine 97 by valine in  $\alpha 1(XI)$  collagen. *Hum Mol Genet* 1996;5:1339-43.
- 7 Martin S, Richards AJ, Yates JRW, *et al.* Stickler syndrome: further mutations in COL11A1 and evidence for additional locus heterogeneity. *Eur J Hum Gen* 1999;7:807-14.
- 8 Ahmad NN, Ala-Kokko L, Knowlton RG, *et al.* Stop codon in the procollagen II gene (COL2A1) in a family with the Stickler syndrome (arthro-ophthalmopathy). *Proc Natl Acad Sci USA* 1991;88:6624-7.
- 9 Williams CJ, Ganguly A, Considine E, *et al.* A→G Transition at the 3' acceptor splice site of IVS17 characterises the COL2A1 gene mutation in the original Stickler syndrome kindred. *Am J Med Genet* 1996;63:461-7.
- 10 Horton WA. Progress in human chondrodysplasia: molecular genetics. *Ann NY Acad Sci* 1996;785:150-9.
- 11 Mayne R, Brewton RG, Mayne PM, *et al.* Isolation and characterization of the chains of type V/type XI collagen present in bovine vitreous. *J Biol Chem* 1993;268:9381-6.
- 12 Sirko-Osadsa D, Murray MA, Scott JA, *et al.* Stickler syndrome without eye involvement is caused by mutations in COL11A2, the gene encoding the  $\alpha 2(XI)$  chain of type XI collagen. *J Pediatr* 1998;132:368-71.
- 13 Brunner HG, van Beersum SEC, Warman ML, O *et al.* A Stickler syndrome gene is linked to chromosome 6 near the COL11A2 gene. *Hum Mol Genet* 1994;3:1561-4.
- 14 Van Steensel MAM, Buma P, de Waal Malefijt MC, *et al.* Otospondylomegapiphysal dysplasia (OSMED): clinical description of three patients homozygous for a missense mutation in the COL11A2 gene. *Am J Med Genet* 1997;70: 315-23.
- 15 Pihlajamaa T, Prockop DJ, Faber J, *et al.* Heterozygous glycine substitution in the COL11A2 gene in the original patient with the Weissenbacher-Zweymüller syndrome demonstrates its identity with heterozygous OSMED (nonocular Stickler syndrome). *Am J Med Genet* 1998;80: 115-20.
- 16 Vikkula M, Mariman ECM, Lui VCH, *et al.* Autosomal dominant and recessive osteochondrodysplasias associated with the COL11A2 locus. *Cell* 1995;80:431-7.
- 17 Wilkin DJ, Mortier GR, Johnson CL, *et al.* Correlation of linkage data with phenotype in eight families with Stickler syndrome. *Am J Med Genet* 1998;80:121-7.
- 18 Sandell LJ, Morris N, Robbins JR, *et al.* Alternatively spliced typeII procollagen mRNAs define distinct populations of cells during vertebral development: differential expression of the amino-propeptide. *J Cell Biol* 1991;114:1307-19.
- 19 Bishop PN, Reardon AJ, McLeod D, *et al.* Identification of alternatively spliced variants of type II procollagen in vitreous. *Biochem Biophys Res Com* 1994;203:289-95.
- 20 Wagner H. Ein bisher unbekanntes Erbleiden des Auges (Degeneratio hyaloideo-retinalis hereditaria), beobachtet im Kanton Zurich. *Klin Monatsbl Augenheilkd* 1938;100: 840-57.
- 21 Bohringer Von HR, Dieterle P, Landolt E. Zur klinik und pathologie der Degeneratio hyaloideo-retinalis hereditaria (Wagner). *Ophthalmologica* 1960;139:330-8.
- 22 Zech JC, Morle L, Vincent P, *et al.* Wagner vitreoretinal degeneration with genetic linkage refinement on chromosome 5q13-q14. *Graefes Arch Clin Exp Ophthalmol* 1999; 237:387-93.
- 23 Scott JD. *Surgery for retinal and vitreous disease*. 1st ed. Oxford: Butterworth-Heinemann, 1998:183-4.
- 24 Brown DM, Graemiger RA, Hergersberg M, *et al.* Genetic linkage of Wagner disease and lobes vitreoretinopathy to chromosome 5q13-14. *Arch Ophthalmol* 1995;113:671-5.
- 25 Perveen R, Hart-Holden N, Dixon MJ, *et al.* Refined genetic and physical localisation of the Wagner disease (WGN1) locus and the genes CRTLL1 and CSPG2 to a 2- to 2.5Cm region of chromosome 5q14.3. *Genomics* 1999;57:219-26.
- 26 Liberfarb RM, Hirose T, Holmes LB. The Wagner-Stickler syndrome: a study of 22 families. *J Pediatr* 1981;99:394-9.
- 27 Liberfarb RM, Hirose T. The Wagner-Stickler syndrome. *Birth Defects: Original Articles Series* 1982;18:525-38.
- 28 Billington BM, Leaver PK, McLeod D. Management of retinal detachment in the Wagner-Stickler syndrome. *Trans Ophthalmol Soc UK* 1985;104:875-9.
- 29 Fryer AE, Upadhyaya M, Littler M, *et al.* Exclusion of COL2A1 as a candidate gene in a family with Wagner-Stickler syndrome. *J Med Genet* 1990;27:91-3.
- 30 Hall JG, Froster-Iskenius UG, Allanson JE. *Handbook of normal physical measurements*. New York: Oxford University Press, 1989.
- 31 Beighton P. In: *McKusick's heritable disorders of connective tissue*. 5th ed. St Louis: Mosby, 1993:199-206.
- 32 British Society of Audiology. Recommended procedures for pure tone audiometry using a manually operated instrument. *Br J Audiol* 1981;15:213-16.
- 33 Graemiger RA, Niemyer G, Schneeberger SA, *et al.* Wagner vitreoretinal degeneration. Follow-up of the original pedigree. *Ophthalmology* 1995;102:1830-9.
- 34 Edmund J. Familial retinal detachment. *Acta Ophthalmol* 1961;39:644-54.
- 35 Monin C, Van Effenterre G, Andre-Sereys P, *et al.* Prevention of retinal detachment in Wagner-Stickler disease. Comparative study of different methods. Apropos of 22 cases. *J Fr Ophthalmol* 1994;17:167-74.
- 36 Godel V, Lazar M. Wagner's vitreo-retinal degeneration with generalised epiphysal dysplasia. *Acta Ophthalmol* 1982;60: 469-74.
- 37 Korkko J, Ritvaniemi P, Haataja L, *et al.* Mutation in type II procollagen (COL2A1) that substitutes aspartate for glycine  $\alpha 1-67$  and that causes cataracts and retinal detachment: evidence for molecular heterogeneity in the Wagner syndrome and Stickler syndrome (Arthro-ophthalmopathy). *Am J Hum Genet* 1993;53:55-61.
- 38 Snead MP, Yates JRW. Clinical and molecular genetics of Stickler syndrome. *J Med Genet* 1999;36:353-9.
- 39 Li S, Gallia GL, Prockop DJ, *et al.* Regulation of alternative splicing of a deleted gene of the human type II procollagen in transgenic mice. *Matrix Biol* 1994;14:410.